Equillium, Inc. EQ
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Equillium, Inc. (EQ) is a healthcare company listed in the US with a market value of about $106M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -72%.
About Equillium
Equillium is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. It was profitable in 0 of the last 8 years in our data. Its share count rose by 70% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $41M | $36M | $16M | — | — | — | — |
| Net income | -$22M | -$8M | -$13M | -$62M | -$39M | -$30M | -$26M | -$13M |
| Free cash flow | -$23M | -$19M | -$22M | -$9M | -$32M | -$25M | -$23M | -$8M |
| EPS (diluted) | $-0.39 | $-0.23 | $-0.38 | $-1.85 | $-1.36 | $-1.46 | $-1.47 | $-1.09 |
| Net margin | — | -19.6% | -37.0% | -396.1% | — | — | — | — |
| ROIC | -80.6% | -33.6% | -49.0% | -146.9% | -48.3% | -37.0% | -41.0% | -10.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $8.56, 563% above the current price; targets range from $4.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-0.19 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Equillium pay a dividend?
Not currently.
Is Equillium a good stock to buy?
We do not give buy or sell advice. Equillium scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.